<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:department>School of Life Sciences</gtr:department><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FCD0A324-2F63-4DD2-83A5-4DB904BA5CAC"><gtr:id>FCD0A324-2F63-4DD2-83A5-4DB904BA5CAC</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Marsh</gtr:surname><gtr:orcidId>0000-0001-8845-3562</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BC293ADF-7C59-4CD2-875A-55E6E6654EEC"><gtr:id>BC293ADF-7C59-4CD2-875A-55E6E6654EEC</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Easton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FL024438%2F1"><gtr:id>376A99D9-280A-48DC-BA85-382B1AF3F22A</gtr:id><gtr:title>Small molecule inhibitors for bovine respiratory syncytial virus</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/L024438/1</gtr:grantReference><gtr:abstractText>Infection of cattle with bovine respiratory syncytial virus is a worldwide problem and results in losses of more than &amp;pound;150 million for the UK farming industry alone. We have shown that BRSV and related viruses express an essential protein, M2-2, by using a novel mechanism that relies on the action of a protein, DDX3 that is present in the cells that the viruses infect. If the virus M2-2 protein is not made in sufficient amounts the virus cannot grow effectively. We have identified a number of inhibitors that interfere with the action of the DDX3 protein and as a result prevent production of the M2-2 protein. This treatment prevents the growth of BRSV and its related viruses. We intend to develop these inhibitors as potential drugs to combat the virus.</gtr:abstractText><gtr:fund><gtr:end>2016-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2014-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>194724</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>We have generated a range of potential inhibitors for respiratory syncytial virus. These have been tested in vitro and the four compounds with the best inhibition profile have been tested for their interaction with liver microsopmes to assess feature for potenmtial use in vivo. Two compounds have been tested in mice for tolerance and have been shown to be tolerated without adverse effects at the highest concentrations achievable for oral administration.</gtr:description><gtr:exploitationPathways>We have shown that these compounds are tolerated extremely well in vivo. Wor is required ion some pharacokinetic studies but the data to date shows that this is a potentially promising avenue of reserch in teh area of antiviral delevelopment.</gtr:exploitationPathways><gtr:id>3122499B-4C2D-440C-83EA-A91A9BB87584</gtr:id><gtr:outcomeId>56de994bb5fa12.99774262</gtr:outcomeId><gtr:sectors><gtr:sector>Agriculture, Food and Drink,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">BB/L024438/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>